Biotech News
Related news
ERASErasca2026-09-10 12:00 EST
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
ERASErasca2026-08-24 12:00 EST
Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma
KURAKura Oncology2026-10-02 11:30 EST
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ZNTLZentalis2026-10-01 21:10 EST
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
IDYAIDEAYA Biosciences2026-09-25 10:00 EST
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GERNGeron2026-09-18 20:01 EST
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REPLReplimune Group2026-08-19 20:01 EST
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FATEFate Therapeutics2026-10-02 11:00 EST
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
NRIXNurix Therapeutics2026-10-05 11:00 EST
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
NRIXNurix Therapeutics2026-09-29 11:00 EST
Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
Erasca
RAS/MAPK Precision Oncology Erasca is a clinical-stage precision-oncology company developing therapies for cancers driven by the RAS/MAPK pathway. Its portfolio is designed to address genetically defined tumors through direct RAS inhibition. ERAS-0015 ERAS-0015 is a pan-RAS molecular glue being evaluated in the AURORAS clinical program....
Recent company news
ERASErasca2026-09-10 12:00 EST
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
ERASErasca2026-09-08 11:00 EST
Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
ERASErasca2026-08-24 12:00 EST
Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma
ERASErasca2026-08-11 20:01 EST
Erasca Reports Second Quarter 2026 Business Updates and Financial Results
ERASErasca2026-08-10 20:01 EST
Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Stock data
- Close
- 14.58 USD
- Market cap
- 4.19B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States